Jefferies Downgrades Questcor Pharmaceuticals (QCOR) to Hold, Cuts Target in Half

Jefferies downgraded Questcor Pharmaceuticals (NASDAQ: QCOR) from Buy to Hold with a price target of $30.00 (from $60.00) after yesterday's policy change by Aetna.

The analyst said, "We are downgrading QCOR shares to Hold from Buy as we believe the Aetna policy change is explicit and will not reimburse for Acthar except for infantile spasms, portending a murky outlook for overall reimbursement with increased risks to sales. While Aetna does have an individual case-based appeal process, our conversations with Aetna suggests this is a cumbersome process with ultimate reimbursement limited to a few Rx's."

For an analyst ratings summary and ratings history on Questcor Pharmaceuticals click here. For more ratings news on Questcor Pharmaceuticals click here.

Shares of Questcor Pharmaceuticals closed at $26.35 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• Analysts favorite fintech stock Adyen tumbles after revenue miss
• Morgan Stanley Downgrades Carrefour SA (CA:FP) (CRRFY) to Equalweight